文献速递静脉血栓栓塞慢性静脉疾病

机械取栓治疗癌症患者IVC滤器相关DVT的技术有效性与临床结局

Technical Effectiveness and Clinical Outcomes of Mechanical Thrombectomy in Cancer Patients Presenting with IVC Filter-Associated Deep Venous Thrombosis: A Retrospective Study.
PubMed 文献 · Ann Vasc Surg · 2025-06-17

本研究为单中心回顾性研究,评估机械取栓在癌症合并下腔静脉滤器相关血栓及下肢DVT患者中的技术安全性和有效性。23例患者技术成功率100%,无主要术中并发症,临床缓解率91.3%,Villalta评分从7.32显著降至1.59(P<0.001)。

要点

  • 癌症合并IVC滤器相关DVT患者行机械取栓技术成功率100%,无主要术中并发症。
  • 临床缓解率91.3%,Villalta评分从7.32降至1.59(P<0.001)。
  • 中位总生存期为34.6个月。

核心结论

  • 机械取栓在癌症合并IVC滤器相关血栓患者中安全有效,可减轻静脉血栓栓塞相关症状。

研究设计与样本

  • 单中心回顾性研究,纳入2019年1月至2024年1月期间癌症合并IVC滤器相关血栓及下肢DVT接受机械取栓的患者,共23例。

主要发现

  • 技术成功率为100%,无主要术中并发症(CTCAE≥3级)。
  • 临床缓解率为91.3%(n=21)。
  • 平均Villalta评分从7.32(标准差3.3)显著降至1.59(标准差0.9)(P<0.001)。
  • 中位总生存期为34.6个月。
  • 既往DVT史占91.3%(n=21/23),平均症状持续时间3.2周(范围1天至16周)。

关键数值与推荐

  • 临床缓解定义为Villalta评分症状减轻。
  • 技术成功定义为经数字减影血管造影和/或血管内超声确认受累静脉血栓取出且管腔通畅。
  • 使用的器械包括ClotTriever(17.4%,n=4)、FlowTriever(69.6%,n=16)及两者联合(13%,n=3)。

临床怎么用

  • 对于癌症合并IVC滤器相关血栓及下肢DVT的患者,机械取栓可作为减少静脉血栓栓塞相关症状的安全有效选择。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Deep venous thrombosis (DVT) in the presence of inferior vena cava (IVC) filters represents a challenging situation for the treatment in cancer patients due to the increased mortality and lack of thrombolytic options in this population. This study assessed the technical safety and efficacy of mechanical thrombectomy (MT) in cancer patients who presented with IVC filter-associated thrombosis and associated lower extremity DVT. METHODS: A single-center retrospective study assessed MT in cancer patients who presented with IVC filter-associated thrombosis and lower extremity DVT from January 2019 to January 2024. Clinical response was defined as a reduction in symptoms per the Villalta score. Technical success was defined as the thrombus extraction from the affected vein, with patent lumen confirmed by digital subtraction angiography and/or intravascular ultrasound. RESULTS: In total, 23 consecutive patients were included. The mean patient age was 57 years. Prior history of DVT was noted in 91.3% (n = 21/23) of patients. The mean symptom duration was 3.2 weeks (range: 1 day to 16 weeks). DVT location was unilateral DVT in 39.1% (n = 9), bilateral DVT in 56.5% (n = 13), and isolated IVC thrombosis in 4.3% (n = 1). Devices used included ClotTriever (17.4%, n = 4), FlowTriever (69.6%, n = 16), and a combination of both (13%, n = 3). The technical success rate was 100%, with no major intraprocedural complications (Common Terminology Criteria for Adverse Events ≥ 3). The clinical response rate was 91.3% (n = 21). The mean Villalta score decreased significantly from 7.32 (standard deviation 3.3) to 1.59 (standard deviation 0.9) (P < 0.001). The median overall survival was 34.6 months. CONCLUSION: MT is safe and efficacious in reducing cancer patients' venous thromboembolism-associated symptoms in patients presenting with IVC filter-associated thrombosis.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Khavandi MM, Pourhassan S, Pal K, et al. Technical Effectiveness and Clinical Outcomes of Mechanical Thrombectomy in Cancer Patients Presenting with IVC Filter-Associated Deep Venous Thrombosis: A Retrospective Study. Ann Vasc Surg. 2025. PMID: 40553836. doi:10.1016/j.avsg.2025.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。